Freedman P M, Autry J R, Tokuda S, Williams R C
J Natl Cancer Inst. 1976 Apr;56(4):735-40. doi: 10.1093/jnci/56.4.735.
Prior sc immunization of BALB/c mice with 1 mg isolated M component of MOPC-11 mouse myeloma resulted in significant relative immunity to subsequent sc or ip challenge with 10(4) living cells from the same plasmacytoma. However, challenges of 10(5) and 10(6) tumor cells overcame immune status engendered by preimmunization with M component. Despite evidence for the specificity of the immunity induced by one isolated M component as opposed to another, no clear cytotoxic antibody, cell-mediated tumor-cell lysis, or predominance of either humoral or cell-mediated immune mechanisms were demonstrated. These findings were compatible with a relatively slight tumor-specific antigenicity of M components expressed on tumor surfaces, compared with the tumor specificity of other tumor-related, cell-surface antigens.
用1毫克分离的MOPC-11小鼠骨髓瘤M成分对BALB/c小鼠进行皮下免疫,可使其对随后皮下或腹腔注射来自同一浆细胞瘤的10⁴个活细胞产生显著的相对免疫力。然而,用10⁵和10⁶个肿瘤细胞进行攻击可克服预先用M成分免疫所产生的免疫状态。尽管有证据表明一种分离的M成分诱导的免疫具有特异性,与另一种M成分不同,但未证明有明确的细胞毒性抗体、细胞介导的肿瘤细胞裂解,也未证明体液免疫或细胞介导免疫机制占主导地位。与其他肿瘤相关的细胞表面抗原的肿瘤特异性相比,这些发现与肿瘤表面表达的M成分相对较弱的肿瘤特异性抗原性相符。